Resources

mRNA for Antibody Manufacturing In collaboration, Charles River Lab and Vernal Biosciences released this scientific poster. Since its release, new advancements have been made and new data is available to share. Join the webinar on December 12 to dive into this new data and hear from the researchers directly.  GET REGISTERED Clinical Trial: mRNA COVID-19…

In this talk, we dive into the critical quality attributes (CQAs) of mRNA and lipid nanoparticles (LNPs) that directly impact drug efficacy and safety. You’ll gain insights into essential and cutting-edge analytical techniques and nanopore sequencing, mass spectrometry, and laser-induced fluorescence capillary gel electrophoresis. Mastering these methods and CQAs is vital for drug developers looking…

New Leadership Reflects Commitment to Advancing mRNA Technologies and Operational Excellence, Helping Drug Developers Deliver Innovative Therapies Faster. COLCHESTER, Vt., October 31, 2024 /BUSINESS WIRE/ — Vernal Biosciences Inc., a leader in mRNA and lipid nanoparticle (LNP) development, manufacturing, and analytics, today announces the appointment of Jim Petrilla as Chief Executive Officer (CEO) and Board…

Nature Nanotechnology: Tissue-Specific mRNA Therapeutic Delivery Researchers have developed a combinatorial design of siloxane-incorporated LNPs to enhance tissue-specific mRNA therapeutic delivery. This article explains how this approach improves intracellular processing and stability of mRNA, showing promise for targeted treatments and efficient gene expression in various tissues. READ MORE Nobel Prize in Physiology or Medicine Victor…

In this video series exploring biotech innovation, Christian Cobaugh, founder and CEO of Vernal, discusses the critical role of analytical services in the success of mRNA and lipid nanoparticles (LNPs) therapeutics. Interviewed by Kristyn Cook, Executive Director of Marketing, he emphasizes the importance of specialized analytical services in maintaining quality, addressing market needs, and meeting…

COLCHESTER, Vt., October 9, 2024 — Vernal Biosciences, a leader in mRNA and lipid nanoparticle (LNP) manufacturing, announces that its analytical and quality control (QC) services for plasmid DNA, mRNA, and LNPs are now commercially available as part of its seamless mRNA platform. These integrated services are the result of extensive development and validation to…